🔎 Trials Near Me

Home › Peripheral Arterial Disease › NCT04774159

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

RecruitingPhase 3

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk: A Randomized Trial

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion criteria:

1. Age \> 18 years
2. Symptomatic atherosclerotic LE PAD fulfilling at least one of the following:

   a. Intermittent claudication with ankle/arm blood pressure ratio\* (ABI ≤ 0.90) or artery stenosis ≥ 50% plus one of i. \>1 vascular bed affected by atherosclerosis ii. Diabetes iii. Heart failure iv. Chronic kidney disease (eGFR \< 60 mL/min/1.73 m2)

   b. Rest pain (mostly in foot) OR necrosis of limb OR gangrene of limb (corresponding to either Fontaine stages 3 or 4 OR Rutherford Classification categories 4 to 6). All must have an ankle/arm blood pressure ratio\* (ABI ≤ 0.90) OR artery stenosis ≥ 50%.

   \* In cases of incompressible ankle arteries, the presence of toe pressure ≤ 60 mm Hg or toe-brachial index ≤ 0.70 is acceptable

   c. Revascularization defined as limb bypass surgery or endovascular revascularization procedures (irrespective of the specific device used), including percutaneous transluminal angioplasty/stent of iliac or infra-inguinal arteries or extra-anatomical bypass surgery

   d. Leg or foot amputation for arterial vascular indications
3. Written or verbal informed consent from the patient

Exclusion Criteria:

1. Contraindication to colchicine
2. Long term requirement for colchicine for another clinical indication
3. Active diarrhoea
4. eGFR \< 30 mL/min/1.73 m2
5. Cirrhosis or severe chronic liver disease
6. Woman who is pregnant, or breast-feeding or of child-bearing potential not protected by reliable contraception or is planning conception during the study
7. Current or planned long term use of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics (with the exception of azithromycin)
8. Patients who are deemed unlikely to return for follow-up
9. Patients with life expectancy \< 1 year

About the study

The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.

What is being tested

Sponsor: Population Health Research Institute · Participants: 6,150 · Started: May 6, 2021

Contact the study team

Official record on ClinicalTrials.gov — NCT04774159

Locations in the U.S.

ConnecticutYale School of Medicine, New Haven
FloridaUniversity of Florida - Gainesville, Gainesville
Tampa General Hospital, Tampa
IllinoisUniversity of Chicago Medical Center, Chicago
MichiganHenry Ford Health System, Detroit
MinnesotaMayo Clinic, Rochester
New JerseyRutgers University, Newark
North CarolinaUniversity of North Carolina at Chapel Hill, Chapel Hill
Duke Regional Hospital, Durham
Duke University Medical Center, Durham
Duke Raleigh Hospital, Raleigh
OhioOhio State University Wexner Medical Center, Columbus
TennesseeVanderbilt University Medical Center, Nashville
TexasSouthwest Family Medicine, Dallas
University of Texas Southwestern Medical Center, Dallas
Texas Tech University Health Sciences, Lubbock
VirginiaSentara Norfolk General Hospital, Norfolk
WashingtonUniversity of Washington Medical Center, Seattle
WisconsinMedical College of Wisconsin, Milwaukee

Conditions

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.